Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017037300) VARLITINIB FOR USE IN THE TREATMENT OF RESISTANT OR REFRACTORY CANCER
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/037300 International Application No.: PCT/EP2016/070893
Publication Date: 09.03.2017 International Filing Date: 05.09.2016
Chapter 2 Demand Filed: 03.07.2017
IPC:
A61K 31/51 (2006.01) ,A61P 35/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
506
not condensed and containing further heterocyclic rings
51
Thiamines, e.g. vitamin B1
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
ASLAN PHARMACEUTICALS PTE LIMITED [SG/SG]; 83 Clemenceau Avenue, #12-03 UE Square, Singapore, 239920., SG
STERLING IP [GB/GB]; Orion House Bessemer Road Welwyn Garden City Hertfordshire AL7 1HH, GB (TT)
Inventors:
LINDMARK, Bertil; SG
OOI, Lisa; SG
Agent:
STERLING IP; Orion House Bessemer Road Welwyn Garden City Hertfordshire AL7 1HH, GB
HAMBLETON, Bernadette; GB
Priority Data:
1515712.604.09.2015GB
1515714.204.09.2015GB
1515716.704.09.2015GB
1515718.304.09.2015GB
1605583.201.04.2016GB
1608660.517.05.2016GB
62/217,33211.09.2015US
62/217,34611.09.2015US
Title (EN) VARLITINIB FOR USE IN THE TREATMENT OF RESISTANT OR REFRACTORY CANCER
(FR) VARLITINIB DESTINÉ À UNE UTILISATION DANS LE TRAITEMENT DE CANCERS RÉSISTANTS OU RÉFRACTAIRES
Abstract:
(EN) The present disclosure provides a method of treating a patient with refractory or resistant cancer by administering a therapeutically effective amount of a compound of formula (I), such as Varlitinib, or an enantiomer thereof or a pharmaceutically acceptable salt of any one of the same. Also provided is a compound of formula (I) for use in the treatment of resistant or refractory cancer and use of a compound of formula (I) for the manufacture of a medicament for the treatment of resistant or refractory cancer.
(FR) La présente invention concerne une méthode de traitement de patients atteint d'un cancer résistant ou réfractaire par l'administration d'une quantité thérapeutiquement efficace d'un composé de formule (I), tel que le Varlitinib, ou d'un énantiomère de ce dernier ou d'un sel pharmaceutiquement acceptable de n'importe lequel d'entre eux. L'invention concerne également un composé de formule (I) destiné à une utilisation dans le traitement de cancers résistants ou réfractaires, et une utilisation d'un composé de formule (I) pour la fabrication d'un médicament pour le traitement de cancer résistants ou réfractaires.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)